Adolore BioTherapeutics to Present at Festival of Biologics USA 2025

by AdoloreJTC24 | Apr 23, 2025 | Press Releases

DELRAY BEACH, FL / ACCESS Newswire / April 23, 2025 / Adolore BioTherapeutics (“Adolore” or the “Company”) is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to...

Adolore BioTherapeutics to Present CA8* Neuromodulating Gene Therapy at the 2025 NANS Annual Meeting

by AdoloreJTC24 | Feb 4, 2025 | Press Releases

DELRAY BEACH, FL / ACCESS Newswire / February 4, 2025 / Adolore BioTherapeutics (“Adolore” or the “Company”), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS...

Adolore BioTherapeutics to Present at 18th Annual Pain Therapeutics Summit

by AdoloreJTC24 | Oct 2, 2024 | Press Releases

DELRAY BEACH, FL / October 2, 2024 / Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company developing transformational opioid-free intracellularly-delivered treatments for chronic pain, today announced that Roy C....

Adolore BioTherapeutics to Present at BioSparkVA Pitch Event

by AdoloreJTC24 | Sep 24, 2024 | Press Releases

DELRAY BEACH, FL / September 24, 2024 / Adolore BioTherapeutics, Inc., (“Adolore” or the “Company”), a biotechnology company developing transformational opioid-free intracellularly-delivered treatments for chronic pain, today announced that Roy...

Adolore BioTherapeutics Announces Issuance of First Japanese Patent Covering CA8* Long-Acting Local Analgesic Therapies to Treat Chronic Pain

by AdoloreJTC24 | Sep 4, 2024 | Press Releases

Patent and novel, potent CA8* nonopioid analgesic licensed by Adolore BioTherapeutics from the University of MiamiCompany is advancing development of rdHSV-CA8* gene therapy delivered intracellularly for the treatment of chronic osteoarthritis (OA) knee pain toward an...